CA Patent

CA3219401A1 — Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients

Assigned to AstraZeneca AB · Expires 2022-11-17 · 3y expired

What this patent protects

The disclosure relates to methods and compositions for the treatment of Systemic Lupus Erythematosus (SLE).

USPTO Abstract

The disclosure relates to methods and compositions for the treatment of Systemic Lupus Erythematosus (SLE).

Drugs covered by this patent

Patent Metadata

Patent number
CA3219401A1
Jurisdiction
CA
Classification
—
Expires
2022-11-17
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.